Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
20. Oktober 2022 17:15 ET
|
Summit Therapeutics Inc.
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole preserved the gut microbiome compared to...
Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
13. Oktober 2022 08:00 ET
|
Summit Therapeutics Inc.
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product candidate, ridinilazole, will have an oral podium...
Summit Therapeutics Closes Fully-Subscribed $100 Million Rights Offering
09. August 2022 13:37 ET
|
Summit Therapeutics Inc.
Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today announced the successful closing of its fully-subscribed...
Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President
26. Juli 2022 16:15 ET
|
Summit Therapeutics Inc.
Menlo Park, California, July 26, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) announces that Dr. Maky Zanganeh, DDS, MBA, has been appointed as Co-Chief Executive Officer &...
Summit Therapeutics Announces Commencement of $100 Million Rights Offering
18. Juli 2022 16:05 ET
|
Summit Therapeutics Inc.
Menlo Park, CA, July 18, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to $100 million of the...
Summit Therapeutics Provides Update on Ridinilazole
14. Juli 2022 08:30 ET
|
Summit Therapeutics Inc.
Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today provided an update with respect to the clinical development of...
Summit Therapeutics Announces $100 Million Rights Offering
22. Juni 2022 16:30 ET
|
Summit Therapeutics Inc.
Menlo Park, CA, June 22, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company’s Board of Directors has approved a rights...
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022
11. Mai 2022 16:30 ET
|
Summit Therapeutics Inc.
Cambridge, MA, May 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational...
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021
17. März 2022 16:14 ET
|
Summit Therapeutics Inc.
Cambridge, MA, March 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its...
Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
05. Januar 2022 07:30 ET
|
Summit Therapeutics Inc.
Cambridge, Massachusetts, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it will present the Company’s vision...